Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS North America Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certifications and Educational Credits
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Preview AMS TV
Features
AMS Features
News & Publications
AMS Bookstore
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series
By
- AMS
posted
Jun 11, 2020 11:01 AM
0
Recommend
.
0 comments
0 views
Permalink
Related Content
Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review
- AMS
Added Apr 21, 2020
Blog Entry
Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis
- AMS
Added Apr 01, 2020
Blog Entry
Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States
- AMS
Added Jun 30, 2020
Blog Entry
Management of adolescents with hidradenitis suppurativa
- AMS
Added Jan 24, 2020
Blog Entry
Psychosocial impact of hidradenitis suppurativa: a practical guide for clinicians
- AMS
Added Jun 14, 2021
Blog Entry
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic